Cerevel Therapeutics Holdings, Inc. (CERE)
NASDAQ (CM) NASDAQ (CM) Primary Summary
The Schall Law Firm Is Performing A Scrutiny Into Cerevel Therapeutics Holdings Inc And Proprietors Of CERE Shares Are Welcomed To Engage
LOS ANGELES, CA / ACCESSWIRE / July 1, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Cerevel Therapeutics Holdings, Inc. ("Cerevel" or "the Company") (NASDAQ:CERE) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Cerevel board breached its fiduciary duties to shareholders.
The Schall Law Firm Is Carrying Out An Inquiry Into Cerevel Therapeutics Holdings Inc And Possessors Of CERE Shares Are Requested To Be Part Of It
LOS ANGELES, CA / ACCESSWIRE / June 30, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Cerevel Therapeutics Holdings, Inc. ("Cerevel" or "the Company") (NASDAQ:CERE) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Cerevel board breached its fiduciary duties to shareholders.
The Schall Law Firm Is Undertaking An Investigation Into Cerevel Therapeutics Holdings Inc And Holders Of CERE Shares Are Encouraged To Participate
LOS ANGELES, CA / ACCESSWIRE / June 29, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Cerevel Therapeutics Holdings, Inc. ("Cerevel" or "the Company") (NASDAQ:CERE) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Cerevel board breached its fiduciary duties to shareholders.
Cerevel Therapeutics Holdings, Inc. (CERE) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Cerevel Therapeutics Holdings, Inc. ever had a stock split?
Cerevel Therapeutics Holdings, Inc. Profile
| Biotechnology Industry | Healthcare Sector | Ronald C. Renaud Jr., CEO | NASDAQ (CM) Exchange | 15678U128 CUSIP |
| US Country | 355 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Cerevel Therapeutics Holdings, Inc. is a clinical-stage biopharmaceutical company deeply immersed in the development of innovative therapies for neuroscience diseases. With its headquarters centrally located in Cambridge, Massachusetts, Cerevel has positioned itself as a leader in the exploration of neurological treatment advancements in the United States. Since its inception in 2018, the company has made significant strides, particularly notable for its commitment to addressing a wide range of neurological conditions with a robust pipeline of dynamic therapies. Cerevel’s affiliation with pharmaceutical giant AbbVie Inc., under which it operates as a subsidiary as of August 1, 2024, underscores its substantial capability and resources for driving forward its mission of tackling unmet medical needs within the neuroscience domain.
Products and Services
Cerevel Therapeutics boasts a diverse and innovative portfolio aiming at the treatment of various neurological disorders through rigorous clinical trials:
- Emraclidine: A Positive Allosteric Modulator (PAM) currently in phase 1b clinical trials, targeting the treatment of schizophrenia. Emraclidine is designed to modulate neuroreceptors in a way that enhances therapeutic effects while minimizing side effects, representing a potentially groundbreaking approach to managing schizophrenia symptoms.
- Darigabat: Another PAM, it is navigating through Phase 2 proof-of-concept trials in patients with drug-resistant focal onset seizures or focal epilepsy. Additionally, it is in a phase 1 trial aimed at treating panic symptoms model. Darigabat’s therapeutic approach could offer hope for individuals with challenging-to-treat epileptic conditions.
- Tavapadon: This selective dopamine D1/D5 partial agonist is advancing through a phase 3 clinical trial, focusing on the treatment of both early- and late-stage Parkinson’s disease. Tavapadon represents a promising potential therapy aimed at easing the symptoms associated with Parkinson’s through its novel mechanism of action.
- CVL-871: A selective dopamine D1/D5 partial agonist like Tavapadon, but it is in a Phase 2a clinical trial to address dementia-related apathy. This condition significantly affects the quality of life for individuals with dementia, and CVL-871 could provide a targeted therapeutic option.
- CVL-354: This compound is a selective kappa-opioid receptor antagonist, currently in exploratory stages for treating major depressive disorder and substance use disorder. By targeting the kappa-opioid receptor, CVL-354 might offer a new avenue for the treatment of depression and addiction, areas of high unmet medical need.
- The company is also pioneering the development of an M4 agonist program aimed at the treatment of psychosis and related indications. This innovative approach could pave the way for new treatments that significantly improve symptoms of psychosis and related conditions.
- Lastly, Cerevel is working on a PDE4 inhibitor, exploring its potential in treating psychiatric, neuroinflammatory, and other disorders. PDE4 inhibitors have been of interest in drug development due to their broad therapeutic potential, and Cerevel’s program is exploring this pathway to uncover new treatment opportunities.
